Table 5

Calculated cumulative cancer incidences from 25 to 40, 50, 60 or 70 years of age for any cancer and for selected groups of cancers occurring as first cancer, by gender and by mutated gene

Selected groupAge (years)Calculated cumulative cancer incidence to given age (95% CI) by group and mutated gene
MLH1MSH2MSH6PMS2
Any cancer, males and females4017% (12.2 to 21.3)14% (8.3 to 20.3)0% (–)0% (–)
5040% (34.7 to 45.7)37% (29.4 to 45.1)18% (8.0 to 28.3)0% (–)
6059% (52.8 to 64.6)58% (49.3 to 65.9)39% (25.8 to 52.2)18% (0.0 to 41.0)
7072% (64.7 to 78.7)72% (61.9 to 81.2)54% (38.6 to 68.6)18% (0.0 to 41.0)
Any cancer, males4019% (12.1 to 25.8)8% (1.2 to 14.3)0% (–)0% (–)
5040% (31.7 to 47.7)25% (14.3 to 35.5)15% (0.0 to 31.3)0% (–)
6055% (46.7 to 64.4)47% (33.3 to 60.8)25% (6.0 to 44.5)0% (–)
7059% (49.7 to 68.6)71% (52.7 to 89.8)31% (10.3 to 52.3)0% (to)
Any cancer, females4014% (8.4 to 20.5)20% (10.6 to 29.7)0% (–)0% (–)
5041% (32.9 to 48.0)47% (36.2 to 57.8)20% (6.9 to 33.6)0% (–)
6061% (53.2 to 68.8)67% (56.6 to 77.0)48% (30.5 to 65.6)24% (0.0 to 53.2)
7080% (71.2 to 88.8)75% (64.5 to 85.6)71% (51.8 to 90.5)24% (0.0 to 53.2)
CRC, males and females4014% (10.0 to 18.7)9% (4.2 to 14.1)0% (–)0% (–)
5027% (22.2 to 32.7)18% (11.4 to 24.4)2% (0.0 to 5.6)0% (–)
6037% (31.0 to 43.4)24% (16.1 to 32.0)10% (0.5 to 19.6)0% (–)
7046% (37.1 to 54.1)35% (22.4 to 47.1)20% (4.4 to 35.4)0% (–)
CRC, males4017% (10.3 to 23.5)8% (1.2 to 14.3)0% (–)0% (–)
5033% (25.5 to 41.4)16% (6.7 to 24.5)0% (–)0% (–)
6044% (35.3 to 53.1)26% (18.7 to 44.2)6% (0.0 to 18.8)0% (–)
7047% (36.9 to 56.1)37% (19.5 to 53.6)14% (0.0 to 32.2)0% (–)
CRC, females4011% (6.2 to 17.5)11% (3.1 to 18.3)0% (–)0% (–)
5021% (14.6 to 28.3)20% (10.6 to 29.6)3% (0.0 to 9.8)0% (–)
6030% (21.9 to 38.9)22% (12.2 to 32.5)12% (0.0 to 25.9)0% (–)
7045% (31.1 to 59.3)33% (16.3 to 48.9)26% (0.0 to 54.2)0% (–)
Endometrial cancer, females403% (0.1 to 5.9)2% (0.0 to 4.7)0% (–)0% (–)
5018% (11.3 to 24.7)15% (6.0 to 24.6)16% (3.1 to 28.6)0% (–)
6034% (24.2 to 44.3)44% (29.3 to 58.2)40% (19.5 to 61.4)24% (0.0 to 52.8)
7034% (24.2 to 44.3)51% (32.7 to 69.2)49% (25.3 to 73.5)24% (0.0 to 52.8)
Ovarian cancer, females401% (0.0 to 3.6)4% (0.0 to 8.9)0% (–)0% (–)
507% (2.2 to 11.2)12% (4.2 to 20.2)0% (–)0% (–)
609% (2.9 to 13.2)15% (5.5 to 24.4)0% (–)0% (–)
7011% (3.2 to 19.8)15% (5.5 to 24.4)0% (–)0% (–)
Upper GI cancer; males and females400.4% (0.0 to 1.1)0% (−)0%(–)0% (–)
502% (0.5 to 4.1)3% (0.0 to 5.7)0%(–)0% (–)
607% (2.4 to 10.4)5% (0.6 to 10.5)2% (0.0 to 6.3)0% (–)
7018% (7.2 to 27.6)5% (0.6 to 10.5)2% (0.0 to 6.3)0% (–)
Urinary tract cancer; males and females400% (−)0% (−)0% (–)0% (–)
501% (0.0 to 2.2)1% (0.0 to 2.3)4% (0.0 to 9.4)0% (–)
602% (0.0 to 3.3)7% (1.8 to 15.1)4% (0.0 to 9.4)0% (–)
702% (0.0 to 3.3)20% (4.1 to 33.9)9% (0.0 to 19.3)0% (–)
  • Cancers included were colorectal (CRC), endometrial, ovarian, upper GI (including gastric, pancreatic, biliary tract and duodenal cancers) and urinary tract cancers (including kidney, calyx, ureter and urinary bladder) in LS patients without prior or prevalent cancer at first colonoscopy.